Results 11 to 20 of about 249,317 (377)
Accelerated Amyloid Beta Pathogenesis by Bacterial Amyloid FapC [PDF]
Advanced Science, 2020 The gut–brain axis has attracted increasing attention in recent years, fueled by accumulating symptomatic, physiological, and pathological findings. In this study, the aggregation and toxicity of amyloid beta (Aβ), the pathogenic peptide associated with ...
Ibrahim Javed +10 more
doaj +6 more sources
Destruxin E Decreases Beta-Amyloid Generation by Reducing Colocalization of Beta-Amyloid-Cleaving Enzyme 1 and Beta-Amyloid Protein Precursor [PDF]
Neurodegenerative Diseases, 2009 Alzheimer-disease-associated beta-amyloid (A beta) is produced by sequential endoproteolysis of beta-amyloid protein precursor (beta APP): the extracellular portion is shed by cleavage in the juxtamembrane region by beta-amyloid-cleaving enzyme (BACE ...
Dohi, Keiji +27 more
core +5 more sources
Plasma pyroglutamate‐modified amyloid beta differentiates amyloid pathology
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2020 Introduction Pyroglutamate‐modified amyloid β (AβpE3) could be a biomarker for Aβ plaque pathology in the brain. An ultra‐high‐sensitive assay is needed for detecting AβpE3‐40.
Pei‐Ning Wang +6 more
doaj +4 more sources
Amyloid‐Beta Interaction with Mitochondria [PDF]
International Journal of Alzheimer’s Disease, 2011 Mitochondrial dysfunction is a hallmark of amyloid‐beta(Aβ)‐induced neuronal toxicity in Alzheimer′s disease (AD). The recent emphasis on the intracellular biology of Aβ and its precursor protein (AβPP) has led researchers to consider the possibility that mitochondria‐associated and/or intramitochondrial Aβ may directly cause neurotoxicity.
Pagani, Lucia, Eckert, Anne
openaire +3 more sources
Beta-amyloid imaging with florbetaben [PDF]
Clinical and Translational Imaging, 2015 Florbetaben is a fluorine-18 (18F)-labeled stilbene derivative that was developed as a positron emission tomography (PET) tracer for routine clinical application to visualize β-amyloid plaques in the Alzheimer's disease (AD) brain. The tracer successfully completed a global multicenter phase 0-III development program and was, as a consequence, recently
Sabri, O, Seibyl, J, Rowe, C, Barthel, H
openaire +3 more sources
Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE® system
Annals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 1898-1909, December 2022., 2022 Abstract Objectives Cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) are well‐established in research settings, but their use in routine clinical practice remains a largely unexploited potential. Here, we examined the relationship between CSF biomarkers, measured by a fully automated immunoassay platform, and brain β‐amyloid (Aβ ...
Hisashi Nojima +9 more
wiley +1 more source
Amyloid-beta and Alzheimer’s disease: the role of neprilysin-2 in amyloid-beta clearance [PDF]
Frontiers in Aging Neuroscience, 2014 Accumulation of the amyloid-beta (Aβ) peptide is a central factor in Alzheimer's disease (AD) pathogenesis as supported by continuing evidence. This review concisely summarizes this evidence supporting a critical role for Aβ in AD before discussing the clearance of this peptide.
Daniel M. Hafez, Robert A. Marr
openaire +4 more sources
Vascular endothelial‐cadherin as a marker of endothelial injury in preclinical Alzheimer disease
Annals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 1926-1940, December 2022., 2022 Abstract Objective Endothelial dysfunction is an early and prevalent pathology in Alzheimer disease (AD). We here investigate the value of vascular endothelial‐cadherin (VEC) as a cerebrospinal fluid (CSF) marker of endothelial injury in preclinical AD.
Rawan Tarawneh +5 more
wiley +1 more source
COVID‐19 and the risk of Alzheimer's disease, amyotrophic lateral sclerosis, and multiple sclerosis
Annals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 1953-1961, December 2022., 2022 Abstract Background The coronavirus disease 2019 (COVID‐19) pandemic has had an unprecedented impact on the healthcare system, economy, and society. Studies have reported that COVID‐19 may cause various neurologic symptoms, including cognitive impairment.
Hanyu Zhang, Zengyuan Zhou
wiley +1 more source
Annals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 1962-1973, December 2022., 2022 Abstract Objectives Early‐ and late‐onset Alzheimer's disease (EOAD and LOAD) share the same neuropathological traits but show distinct cognitive features. We aimed to explore baseline and longitudinal outcomes of global and domain‐specific cognitive function in a well characterized cohort of patients with a biomarker‐based diagnosis.
Adrià Tort‐Merino +16 more
wiley +1 more source